Suppr超能文献

淀粉样蛋白原性蛋白的神秘寡聚化。

Mysterious oligomerization of the amyloidogenic proteins.

机构信息

Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

出版信息

FEBS J. 2010 Jul;277(14):2940-53. doi: 10.1111/j.1742-4658.2010.07721.x. Epub 2010 Jun 10.

Abstract

Misfolding and subsequent self-assembly of protein molecules into various aggregates is a common molecular mechanism for a number of important human diseases. Curing protein misfolding pathologies and designing successful drugs for the inhibition or reversal of protein aggregation depends on understanding the peculiarities of the misfolding process. Protein aggregation is a very complex process characterized by a remarkable polymorphism, where soluble amyloid oligomers, amyloid fibrils and amorphous aggregates are found as final products. This polymorphism is associated with the existence of multiple independent and competing assembly pathways leading to aggregation. Regardless of the aggregation mechanism, soluble oligomers are inevitably formed during the self-association process. Some of these oligomers are now considered to be major initiators of the neurodegenerative cascades of corresponding diseases. However, not all oligomers are equally harmful, and several amyloidogenic proteins have been shown to form nontoxic oligomers, some of which were efficient fibrillation inhibitors. Unfortunately, the information on the structural properties of soluble oligomers and the mechanisms of their formation, interconversion and toxicity is sparse. This review provides an overview of some topics related to soluble oligomers and represents several illustrative examples of toxic, nontoxic, productive and off-pathway amyloid oligomers.

摘要

蛋白质分子错误折叠并随后自组装成各种聚集体,是许多重要人类疾病的常见分子机制。治愈蛋白质错误折叠病变并设计成功的抑制或逆转蛋白质聚集的药物,取决于对错误折叠过程的特殊性的理解。蛋白质聚集是一个非常复杂的过程,其特征是显著的多态性,其中可溶性淀粉样寡聚物、淀粉样纤维和无定形聚集体被发现是最终产物。这种多态性与存在多个独立且竞争的聚合途径导致聚集有关。无论聚集机制如何,可溶性寡聚物在自组装过程中不可避免地形成。其中一些寡聚物现在被认为是相应疾病神经退行性级联反应的主要启动子。然而,并非所有的寡聚物都是同样有害的,已经有研究表明一些淀粉样蛋白可以形成无毒的寡聚物,其中一些是有效的纤维形成抑制剂。不幸的是,关于可溶性寡聚物的结构特性及其形成、相互转化和毒性的机制的信息还很匮乏。这篇综述提供了一些与可溶性寡聚物相关的主题的概述,并展示了几种有代表性的毒性、无毒、产生活性和非通路的淀粉样寡聚物。

相似文献

1
Mysterious oligomerization of the amyloidogenic proteins.淀粉样蛋白原性蛋白的神秘寡聚化。
FEBS J. 2010 Jul;277(14):2940-53. doi: 10.1111/j.1742-4658.2010.07721.x. Epub 2010 Jun 10.
3
Structural, morphological, and functional diversity of amyloid oligomers.淀粉样寡聚体的结构、形态和功能多样性。
FEBS Lett. 2015 Sep 14;589(19 Pt A):2640-8. doi: 10.1016/j.febslet.2015.07.013. Epub 2015 Jul 17.
4
Elucidating the Role of Lipids in the Aggregation of Amyloidogenic Proteins.阐明脂质在淀粉样蛋白聚集中的作用。
Acc Chem Res. 2023 Nov 7;56(21):2898-2906. doi: 10.1021/acs.accounts.3c00386. Epub 2023 Oct 12.
6
Lipid membranes induce structural conversion from amyloid oligomers to fibrils.脂膜诱导淀粉样寡聚体到纤维的结构转换。
Biochem Biophys Res Commun. 2021 Jun 11;557:122-126. doi: 10.1016/j.bbrc.2021.03.174. Epub 2021 Apr 14.
10
Amyloid Oligomers, Protofibrils and Fibrils.淀粉样寡聚体、原纤维和纤维。
Subcell Biochem. 2019;93:471-503. doi: 10.1007/978-3-030-28151-9_16.

引用本文的文献

本文引用的文献

3
Amyloid oligomers: formation and toxicity of Abeta oligomers.淀粉样寡聚物:Abeta 寡聚物的形成和毒性。
FEBS J. 2010 Mar;277(6):1348-58. doi: 10.1111/j.1742-4658.2010.07568.x. Epub 2010 Feb 9.
7
Structure-neurotoxicity relationships of amyloid beta-protein oligomers.淀粉样β蛋白寡聚体的结构与神经毒性关系
Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14745-50. doi: 10.1073/pnas.0905127106. Epub 2009 Aug 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验